Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 159

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 4
Chunk 159
---
 patent, relating to an apparatus for planning an Alpha DaRT treatment session.
The three issued patents include two patents issued in the U. S. and one patent issued in Japan. The 15 patent applications are pending
in Europe, Taiwan, China, Korea, Japan, India, Singapore, Australia, Canada, Mexico, Russia, ARIPO, South Africa, Israel and Hong Kong,
of which the Korean patent application has been allowed. These patents or patents issuing from these pending applications will begin to
expire in 2041, exclusive of possible patent term adjustments or extensions or other forms of exclusivity.

We have one issued patent,
and 16 pending patent applications, including one allowed patent application, relating to a designated applicator which dispenses radioactive
sources in a radial configuration. The one issued patent is in the U. S. The 16 patent applications are pending in the U. S., Taiwan, Europe,
China, Hong Kong, Japan, Korea, India, Singapore, Canada, Russia, ARIPO, South Africa, Mexico, Australia and Israel, of which the patent
application in Australia was allowed. This patent or patents issuing from these pending applications will begin to expire in 2042, exclusive
of possible patent term adjustments or extensions or other forms of exclusivity.

We have nine issued patents,
and 22 pending patent applications, relating to Alpha DaRT as used in tumor-specific treatment applications. The nine issued patents have
been issued in the U. S. and Australia. The 22 pending patent applications are pending in the U. S., Europe, Japan, China, Australia, Hong
Kong, and seven pending patent applications in Taiwan. These patents or patents issuing from these pending applications will begin to
expire in 2041, exclusive of possible patent term adjustments or extensions or other forms of exclusivity.

We have 30 pending patent
applications relating to the combination of Alpha DaRT with checkpoint inhibitor and vasculature inhibitor immunotherapies. Of the 30
pending patent applications, there are two pending patents in each of the U. S., Europe, China, Japan, South Africa, Korea, ARIPO, Israel,
Mexico, Singapore, Australia and Canada, and three pending patents in each of Taiwan and Russia. The patents issuing from these pending
applications will begin to expire in 2042, exclusive of possible patent term adjustments or extensions or other forms of exclusivity.

We have 14 pending patent
applications relating to a calculation for automatic estimation of radiotherapy source